Anaemia and heart failure

Anaemia is one of the most frequent co-morbidities in patients with heart failure. Its prevalence increases from 4% to7% in subjects with asymptomatic left ventricular dysfunction to >30% in patients with severe heart failure. Renal insufficiency, activation of inflammatory mediators and treatment with renin-angiotensin antagonists seem to be its main determinants. The results of many studies agree in providing evidence that anaemia is a powerful independent determinant of survival in patients with heart failure. However, the mechanisms of this relation are still not fully understood. Moreover a favourable effect of the correction of anaemia on prognosis has not yet been shown. Also In addition to this, controlled studies assessing its effects on exercise tolerance have yielded controversial results. Further research is needed to assess the effect of correcting anaemia in chronic heart failure (CHF) patients; ongoing reduction of events with RED-HF (Darbepoetin alpha in heart failure) trial will help define the role.

[1]  J. Hradec.  [Anaemia in chronic heart failure]. , 2010, Vnitrni lekarstvi.

[2]  Jian Li,et al.  A meta‐analysis of erythropoiesis‐stimulating agents in anaemic patients with chronic heart failure , 2010, European journal of heart failure.

[3]  S. Manzano-Fernández,et al.  Red blood cell distribution width predicts long‐term outcome regardless of anaemia status in acute heart failure patients , 2009, European journal of heart failure.

[4]  E. Schwarz,et al.  The prognostic value of anemia in patients with diastolic heart failure. , 2009, Texas Heart Institute journal.

[5]  G. Karanikas,et al.  Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. , 2008, European heart journal.

[6]  I. Anand.  Anemia and chronic heart failure implications and treatment options. , 2008, Journal of the American College of Cardiology.

[7]  R. I. Usmanov,et al.  Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. , 2008, Journal of nephrology.

[8]  Anil K. Jain,et al.  Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. , 2008, Journal of the American College of Cardiology.

[9]  R. Latini,et al.  Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure? , 2008, Heart Failure Reviews.

[10]  P. Armstrong,et al.  Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia , 2008, Circulation.

[11]  C. O'connor,et al.  Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). , 2008, The American journal of cardiology.

[12]  P. Ponikowski,et al.  Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. , 2007, Journal of the American College of Cardiology.

[13]  M. Kruszewski,et al.  Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. , 2008, European heart journal.

[14]  P. Duarte,et al.  Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. , 2007, Journal of the American College of Cardiology.

[15]  A. Nissenson,et al.  The new FDA label for erythropoietin treatment: how does it affect hemoglobin target? , 2007, Kidney international.

[16]  D. Silverberg,et al.  Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. , 2007, American heart journal.

[17]  P. van der Harst,et al.  Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. , 2007, European heart journal.

[18]  D. J. Veldhuisen,et al.  Is anemia in chronic heart failure caused by iron deficiency? , 2007, Journal of the American College of Cardiology.

[19]  J. Griffith,et al.  Anemia as a risk factor for kidney function decline in individuals with heart failure. , 2007, The American journal of cardiology.

[20]  P. Ponikowski,et al.  Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. , 2007, Journal of the American College of Cardiology.

[21]  J. McMurray,et al.  Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial , 2007, European journal of heart failure.

[22]  B. Kanna,et al.  Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) study. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  G. Navis,et al.  Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. , 2006, European heart journal.

[24]  R. Bilous,et al.  Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  D. Karageorgopoulos,et al.  Etiology of anemia in patients with advanced heart failure. , 2006, Journal of the American College of Cardiology.

[26]  A. Voors,et al.  Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. , 2006, Journal of the American College of Cardiology.

[27]  H. Burger,et al.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia. , 2006, The New England journal of medicine.

[28]  Huiman Barnhart,et al.  Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.

[29]  J. McMurray,et al.  Anaemia is an independent predictor of mortality in patients with left ventricular systolic dysfunction following acute myocardial infarction ☆ , 2006, European journal of heart failure.

[30]  A. Bolger,et al.  Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. , 2006, Journal of the American College of Cardiology.

[31]  A. Rigby,et al.  Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. , 2006, The American journal of cardiology.

[32]  A. Go,et al.  Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study , 2006, Circulation.

[33]  P. Poole‐Wilson,et al.  The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. , 2006, European heart journal.

[34]  S. Katz,et al.  Anemia in Chronic Heart Failure: Prevalence, Etiology, Clinical Correlates, and Treatment Options , 2006, Circulation.

[35]  Kdoqi Disclaimer,et al.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[36]  P. Ponikowski,et al.  Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa on hemoglobin response and symptoms in patients with heart failure and anemia , 2006 .

[37]  S. Solomon,et al.  Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program , 2006, Circulation.

[38]  C. O'connor,et al.  Anemia in patients with heart failure and preserved systolic function. , 2006, American heart journal.

[39]  J. Singer,et al.  Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[40]  M. Cazzola,et al.  Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. , 2005, European heart journal.

[41]  J. González-Juanatey,et al.  Anaemia is associated with higher mortality among patients with heart failure with preserved systolic function , 2005, Heart.

[42]  D. J. Veldhuisen,et al.  Levels of Hematopoiesis Inhibitor N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure , 2005, Circulation.

[43]  Cristina Opasich,et al.  Anemia and Change in Hemoglobin Over Time Related to Mortality and Morbidity in Patients With Chronic Heart Failure: Results From Val-HeFT , 2005, Circulation.

[44]  R. Henning,et al.  Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. , 2005, Journal of the American College of Cardiology.

[45]  R. Foley,et al.  Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. , 2005, Journal of the American Society of Nephrology : JASN.

[46]  G. Keren,et al.  Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. , 2005, Archives of internal medicine.

[47]  L. Goodnough,et al.  Anemia of chronic disease. , 2005, The New England journal of medicine.

[48]  L. Tavazzi,et al.  Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. , 2005, Journal of cardiac failure.

[49]  P. Ghezzi,et al.  A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[50]  S. Yusuf,et al.  Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. , 2005, Journal of the American College of Cardiology.

[51]  P. Poole‐Wilson,et al.  Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. , 2004, European heart journal.

[52]  C. O'connor,et al.  Anemia as a risk factor and therapeutic target in heart failure. , 2004, Journal of the American College of Cardiology.

[53]  J. McMurray,et al.  Anemia and Its Relationship to Clinical Outcome in Heart Failure , 2004, Circulation.

[54]  Z. Erbayraktar,et al.  Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic , 2004, Science.

[55]  A. Voors,et al.  Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. , 2004, Journal of the American College of Cardiology.

[56]  J. Cleland,et al.  Are hematinic deficiencies the cause of anemia in chronic heart failure? , 2004, American heart journal.

[57]  D. Sane,et al.  Relation of anemia to diastolic heart failure and the effect on outcome. , 2004, The American journal of cardiology.

[58]  J. Griffith,et al.  Hematocrit and left ventricular mass: the Framingham Heart study. , 2004, Journal of the American College of Cardiology.

[59]  David Voss,et al.  Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. , 2004, Journal of the American Society of Nephrology : JASN.

[60]  Richard B. Thompson,et al.  A novel protective effect of erythropoietin in the infarcted heart. , 2003, The Journal of clinical investigation.

[61]  C. O'connor,et al.  Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. , 2003, The American journal of cardiology.

[62]  P. Ponikowski,et al.  Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. , 2003, International journal of cardiology.

[63]  D. Mozaffarian,et al.  Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). , 2003, Journal of the American College of Cardiology.

[64]  P. Ponikowski,et al.  Effect of anemia on exercise tolerance in chronic heart failure in men. , 2003, The American journal of cardiology.

[65]  Harlan M Krumholz,et al.  The prognostic importance of anemia in patients with heart failure. , 2003, The American journal of medicine.

[66]  C. Lang,et al.  Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure , 2003, Circulation.

[67]  Paul W Armstrong,et al.  Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes: Insights From a Cohort of 12 065 Patients With New-Onset Heart Failure , 2003, Circulation.

[68]  L. Lund,et al.  Hemodilution Is Common in Patients With Advanced Heart Failure , 2003, Circulation.

[69]  O. Hess,et al.  The prevalence of anemia in chronic heart failure. , 2002, International journal of cardiology.

[70]  I. Macdougall,et al.  Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[71]  G. London,et al.  Iron Therapy, Advanced Oxidation Protein Products, and Carotid Artery Intima-Media Thickness in End-Stage Renal Disease , 2002, Circulation.

[72]  M. Díaz-Ricart,et al.  Erythropoietin Triggers a Signaling Pathway in Endothelial Cells and Increases the Thrombogenicity of their Extracellular Matrices In Vitro , 2002, Thrombosis and Haemostasis.

[73]  J. Griffith,et al.  Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. , 2002, Journal of the American College of Cardiology.

[74]  C. Jurkovitz,et al.  Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. , 2002, Journal of the American Society of Nephrology : JASN.

[75]  G. Fonarow,et al.  Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. , 2002, Journal of the American College of Cardiology.

[76]  H. Krumholz,et al.  Blood transfusion in elderly patients with acute myocardial infarction. , 2001, The New England journal of medicine.

[77]  W. Rand,et al.  Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.

[78]  I. Shapira,et al.  The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. , 2001, Journal of the American College of Cardiology.

[79]  E J Fitzsimons,et al.  Anaemia of chronic disease. , 2013, Clinical medicine.

[80]  I. Shapira,et al.  The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. , 2000, Journal of the American College of Cardiology.

[81]  Avid,et al.  THE EFFECTS OF NORMAL AS COMPARED WITH LOW HEMATOCRIT VALUES IN PATIENTS WITH CARDIAC DISEASE WHO ARE RECEIVING HEMODIALYSIS AND EPOETIN , 2000 .

[82]  S. Anker,et al.  Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. , 1999, Chest.

[83]  M. Kanter,et al.  Transfusion medicine. First of two parts--blood transfusion. , 1999, The New England journal of medicine.

[84]  G. Wells,et al.  A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. , 1999, The New England journal of medicine.

[85]  B. Julian,et al.  Angiotensin II stimulates proliferation of normal early erythroid progenitors. , 1997, The Journal of clinical investigation.

[86]  N. Vaziri,et al.  Up-regulation of renal and vascular nitric oxide synthase in iron-deficiency anemia. , 1997, Kidney international.

[87]  Andrew D. Rosenberg,et al.  Practice Guidelines for Blood Component Therapy: A Report by the American Society of Anesthesiologists Task Force on Blood Component Therapy , 1996, Anesthesiology.

[88]  I. Anand,et al.  Endothelium-derived relaxing factor is important in mediating the high output state in chronic severe anemia. , 1995, Journal of the American College of Cardiology.

[89]  G. Condorelli,et al.  Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. , 1994, The American journal of cardiology.

[90]  P. Poole‐Wilson,et al.  Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. , 1993, British heart journal.

[91]  M. Metra,et al.  Improvement in exercise capacity after correction of anemia in patients with end-stage renal failure. , 1991, The American journal of cardiology.

[92]  P. Poole‐Wilson,et al.  Pathogenesis of Edema in Constrictive Pericarditis: Studies of Body Water and Sodium, Renal Function, Hemodynamics, and Plasma Hormones Before and After Pericardiectomy , 1991, Circulation.

[93]  J. Adamson,et al.  Adrenergic modulation of erythropoiesis: in vitro studies of colony‐forming cells in normal and polycythaemic man , 1984, British journal of haematology.

[94]  R. Adolph,et al.  Cardiovascular effects of anemia. , 1972, American heart journal.